THALES
Thales today announced new data protection solutions for Google Cloud, Microsoft Azure, and Amazon Web Services, solidifying its role as a trusted third party for multicloud data security.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210518005282/en/
With each cloud provider having unique data protection mechanisms and key management offerings, multicloud data protection presents a complex security challenge for organisations. Thales’ latest cloud data security solutions allow customers to maintain control of and manage their encryption keys, as well as manage access and authentication across hybrid and multicloud environments.
“These capabilities are critical to cloud migration and security, especially with such accelerated growth in this area,” said Sunil Potti, Vice President and General Manager of Google Cloud Security . “True to our mission, we have forged this collaboration with Thales to further protect our customer’s most sensitive information. We are empowering customers to leverage the full potential of Google Cloud technology for sensitive workloads, by utilising the Customer-Managed Encryption Key-integrated GCP services, CipherTrust Cloud Key Manager and SafeNet Trusted Access for access management and authentication from Thales. This will enable enterprises to deal with a fluid and dynamic business environment where protecting sensitive data in the cloud is of extreme importance.”
Simplifying Multicloud Security
As customers look to reap the rewards from multicloud environments, Thales is making it easier to ensure protection against reputational risk and financial penalties arising from a cloud data breach. As such, customers will benefit from enhanced capabilities to Discover, Protect and Control sensitive data across multicloud environments, including the ability to:
Discover Sensitive Data in the Cloud and On-Premises
Thales Data Discovery and Classification automates the discovery, classification and protection of data in the cloud and on-premises using automation policies that identify sensitive data and protect the data with encryption or tokenisation. These capabilities have now been extended to the discovery and classification of data in Amazon Web Services S3 buckets and Azure Blob storage.
Protect Sensitive Data and Workloads in the Cloud
To address both the complexity of where data is stored and to help ensure data sovereignty in a multicloud environment, effective encryption and tokenisation is needed. Specific new data protection capabilities for cloud platforms include:
- CipherTrust Transparent Encryption for advanced encryption and access controls, protects data in Amazon Web Services Simple Storage Service (S3)
- Encryption of Kubernetes secrets and Google Anthos Service Mesh signing keys
Control Access to Applications and Sensitive Data in the Cloud
The accelerated adoption of encryption has led to the need to manage a far larger number of encryption keys across both traditional data stores and multicloud environments. Thales has enabled new capabilities that allow organisations to control access to data and ownership of their encryption keys, including:
- Thales is also offering CipherTrust Cloud Key Manager support for Google Cloud’s External Key Manager (EKM), building on the existing CipherTrust Key Broker for Google Cloud EKM which is part of the Thales Data Protection on Demand cloud-based platform.
Secure and Protect access at the Login Point
Compromised identities pose one of the greatest risks for data breaches:
- SafeNet Trusted Access integrates out of the box with Google Workspace, Azure and AWS, enforcing the appropriate access controls and authentication for privileged and regular users.
- SafeNet Trusted Access is offering new abilities to provide authentication and authorisation for APIs and for applications not using industry-standard protocols such as SAML and OIDC.
“The proliferation of multicloud computing has created new organizational challenges in managing data across many different cloud environments. Whilst organisations have benefited from scalability and speed to market thanks to the power of cloud, the ever expanding IT cloud landscape has added greater complexity to data management and security,” said Sébastien Cano, Senior Vice President, Cloud Protection and Licensing activities at Thales . “In a post pandemic, highly regulated world, it is even more important for organisations to understand what data they have, where it sits, who can access it and the risks associated with managing it. Only once an organization understands all of these data lifecycle aspects, can they ensure that it is secured and managed correctly.”
Additional Resources
Thales and Google Cloud have forged a strong collaboration to help enterprises migrate sensitive data between public cloud, hybrid and private IT infrastructures. Watch this video with Sunil Potti, VP and GM at Google Cloud Security to learn more.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
Thales Group
Security
View source version on businesswire.com: https://www.businesswire.com/news/home/20210518005282/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
